Glucagen Hypokit

Glucagen Hypokit is a glucagon‑containing injectable product, supplied in a ready‑to‑use kit for intramuscular, intravenous or subcutaneous administration. It is marketed in the European Union and prescribed for the rapid reversal of severe hypoglycemia in patients with diabetes. The kit contains a pre‑filled syringe that delivers a standard dose of glucagon, a peptide hormone that raises blood glucose. Glucagen Hypokit is a prescription medication and is not a controlled substance.

Glucagen Hypokit is indicated for the emergency treatment of severe hypoglycemia when rapid restoration of blood glucose is required.

- Acute hypoglycemic episodes in adults with type 1 or type 2 diabetes who are unable to ingest carbohydrates orally. - Hypoglycemia unresponsive to oral glucose or glucagon‑containing emergency kits. - Use by trained caregivers, healthcare professionals, or patients themselves in a crisis situation. - Administration in a hospital or emergency setting when intravenous dextrose is not immediately available. - Off‑label use may include diagnostic testing of pancreatic function, though this is not a primary indication.

The safety profile of glucagon injection reflects its pharmacologic action on glucose metabolism and the injection site. Because glucagon rapidly raises blood glucose, side effects are often related to the sudden metabolic shift and to the injection technique.

Common: - Nausea or vomiting - Flushing or warmth sensation - Transient headache - Injection site pain, redness or swelling - Dizziness or feeling of light‑headedness

Serious: - Allergic reactions such as rash, urticaria, or anaphylaxis - Severe hypotension - Cardiac arrhythmias in patients with underlying heart disease - Persistent hyperglycemia requiring medical attention - Pancreatitis (rare)

When using Glucagen Hypokit, several precautions should be observed to ensure safe and effective treatment of hypoglycemia.

- Confirm the patient’s diagnosis of severe hypoglycemia before administration. - Do not use if the glucagon solution is discolored, contains particles, or the kit is past its expiration date. - Avoid intramuscular injection in the buttock of infants; subcutaneous or intramuscular injection in the thigh is preferred. - Patients with pheochromocytoma or insulinoma may experience exaggerated blood‑glucose responses. - Pregnancy and lactation status should be assessed, as safety data are limited. - Store the kit at controlled room temperature, protected from light and moisture. - Educate caregivers on proper reconstitution and injection technique.

Glucagon may interact with other medications or medical conditions, influencing its efficacy or safety.

Avoid: - Concurrent use of beta‑blockers may blunt the glucose‑raising effect of glucagon. - Insulin or insulin secretagogues administered shortly before glucagon can increase the risk of rebound hypoglycemia.

Use with caution: - Oral contraceptives and other estrogen‑containing products may alter glucagon metabolism. - Drugs that affect hepatic glycogen stores, such as corticosteroids, may modify response. - Patients receiving catecholamines (e.g., epinephrine) should be monitored for additive cardiovascular effects. - Renal or hepatic impairment may require closer observation of glucose response.